Abstract
Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (1,2). More than 1000 disease mutations and 200 polymorphisms have been identified in the CFTR gene (3). The type and frequency of mutations is very variable from ethnic population to population (4). The most common mutation, F508del (e.g., ΔF508 according to the old nomenclature), reaches frequencies of about 70% in Northern European populations. Besides F508del, other common mutations exist in most populations, each reaching frequencies of approx 1–2%. Examples include the 1717-1G→A, G542X, G551D, R553X, W1282X, and N1303K mutations. Finally, for a given ethnic population, “ethnic-specific” mutation(s) that reach frequencies of more than 1–2% might exist. For most ethnic populations, “common” mutations cover about 85% of all mutant CFTR genes. The remaining group of mutant CFTR genes in a particular ethnic population comprises rare mutations, some of them only found in a single family. Moreover, when one of the more common mutations is not found in a patient, a mutation is likely to be present that has never been detected before in that ethnic population. It is therefore very difficult to set up a strategy for a general screening of CFTR mutations, which allow sensitivities close to 100%, even in a well-characterized ethnic population.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Riordan, J. R., Rommens, J. M., Kerem, B. S., Alon, N., Rozmahel, R., Grzelczak, Z., et al. (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245, 1066–1073.
Zielenski, J., Rozmahel, R., Bozon, D., Kerem, B.-S., Grzelczak, Z., Riordan, J. R., et al. (1991) Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics 10, 214–228.
The Cystic Fibrosis Genetic Analysis Consortium. Cystic Fibrosis Mutation Database. http://www.genet.sickkids.on.ca/cftr/
Dequeker, E., Cuppens, H., Dodge, J., Estivill, X., Goossens, M., Pignatti, P. F., et al. (2000) Recommendations for quality improvement in genetic testing for cystic fibrosis. European Concerted Action on Cystic Fibrosis. Eur. J. Hum. Genet. 8(Sp 2), S2–S24.
Dequeker, E. and Cassiman, J. J. (2000) Genetic testing and quality control in diagnostic laboratories. Nat. Genet. 25, 259–260.
Grody, W. W., Cutting, G. R., Klinger, K. W., Richards, C. S., Watson, M. S., and Desnick, R. J. (2001) Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genetics in Medicine 3, 149–154.
Costes, B., Fanen, P., Goossens, M., and Ghanem, N. (1993) A rapid, efficient, and sensitive assay for simultaneous detection of multiple cystic fibrosis mutations. Hum. Mutat. 2, 185–191.
Cuppens, H. and Cassiman, J.-J. (2001) Solid phase fluorescent sequencing of the CFTR gene, in DNA Sequencing Protocols (Graham, C. A. and Hill, A. J. M., eds.), Humana Press, Totowa, NJ, pp. 63–88.
Le Maréchal, C, Audrézet, M. P., Quéré, I., Raguénès, O., Langonné, S., and Férec, C. (2001) Complete and rapid scanning of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by denaturing high-performance liquid chromatography (D-HPLC): major implications for genetic counselling. Hum. Genet. 108, 290–298.
Zielenski, J., Patrizio, P., Corey, M., Handelin, B., Markiewicz, D., Asch, R., et al. (1995) CFTR gene variant for patients with congenital absence of vas deferens. Am. J. Hum. Genet. 57, 958–960.
Chillón, M., Casals, T, Mercier, B., Bassas, L., Lissens, W., Silber, S., et al. (1995) Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N. Engl. J. Med. 332, 1475–1480.
Pignatti, P. F., Bombieri, C, Marigo, C, Benetazzo, M., and Luisetti, M. (1995) Increased incidence of cystic fibrosis gene mutations in adults with disseminated bronchiectasis. Hum. Mol. Genet. 4, 635–639.
Sharer, N., Schwarz, M., Malone, G., Howarth, A., Painter, J., Super, M., et al. (1998) Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N. Engl. J. Med. 339, 645–652.
Chu, C.-S., Trapnell, B. C, Curristin, S., Cutting, G. R., and Crystal, R. G. (1993) Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nat. Genet. 3, 151–156.
Cuppens, H., Lin, W., Jaspers, M., Costes, B., Teng, H., Vankeerberghen, A., et al. (1998) Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes—The polymorphic (TG)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. J. Clin. Investig. 101, 487–496.
Kiesewetter, S., Macek, M. Jr., Davis, C, Curristin, S. M., Chu, C.-S., Graham, C, et al. (1993) A mutation in CFTR produces different phenotypes depending on chromosomal background. Nat. Genet. 5, 274–278.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Humana Press Inc.
About this protocol
Cite this protocol
Cuppens, H., Dequeker, E., Cassiman, JJ. (2004). Cystic Fibrosis. In: Elles, R., Mountford, R. (eds) Molecular Diagnosis of Genetic Diseases. Methods in Molecular Medicine™, vol 92. Humana Press, Totowa, NJ. https://doi.org/10.1385/1-59259-432-8:221
Download citation
DOI: https://doi.org/10.1385/1-59259-432-8:221
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-0-89603-932-2
Online ISBN: 978-1-59259-432-0
eBook Packages: Springer Protocols